Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with outpatient buprenorphine maintenance, quality of life, and mood.
Epistemonikos ID: 3cc5f7293b46f29faf3edf3fc5b07eddcfaf7931
First added on: May 15, 2024